GlassScriptPhysician profile
Casandra M Spreen
NPI 1598058364
$758.12
in general payments reported to CMS, 2019-2025
22 companies · $14.60 in 2025
The $14.60 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.35 · 2020: $101 · 2021: $172 · 2022: $167 · 2023: $71.92 · 2024: $171 · 2025: $14.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.03 | 2019-2025 | |
| Astellas Pharma US INC | $101.96 | 2023-2024 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $83.04 | 2020-2021 | |
| Lupin INC. | $65.01 | 2019-2021 | |
| Exact Sciences Corporation | $51.76 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.03 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $31.21 | 2019-2024 | |
| Daiichi Sankyo INC. | $24.98 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.94 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $21.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.35 | 2022 | |
| Coopersurgical, INC. | $16.11 | 2020 | |
| Novo Nordisk INC | $15.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.51 | 2024 | Airsupra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $14.50 | 2021 | |
| Avion Pharmaceuticals | $13.70 | 2021 | |
| Minerva Surgical, INC | $13.31 | 2024 | |
| Exeltis, USA INC. | $13.11 | 2021 | |
| Agile Therapeutics, INC. | $12.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.74 | 2022 | |
| Evofem Biosciences, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casandra Spreen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.